Navigating Aetna Skyrizi Prior Authorization with Klivira

Successfully managing Aetna Skyrizi prior authorization is critical for revenue cycle efficiency and timely patient access to this IL-23 inhibitor. Klivira provides the automation and insights needed to navigate Aetna's specific requirements for risankizumab.

Prior authorization for specialty medications like Skyrizi (risankizumab) can be a significant administrative burden, especially when dealing with complex payer requirements. For revenue cycle directors and prior authorization coordinators, understanding Aetna's specific submission channels, medical necessity criteria, and turnaround times is essential to minimize denials and accelerate patient care. Klivira streamlines these processes, integrating directly with your EMR and Aetna's systems.

Understanding Skyrizi and Aetna's Coverage Landscape

Skyrizi, or risankizumab, is an IL-23 inhibitor developed by AbbVie, commonly prescribed for chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a high-cost specialty biologic, Skyrizi typically requires prior authorization from payers like Aetna to ensure medical necessity and appropriate utilization. Aetna's coverage policies and administrative processes govern access to risankizumab for its commercial and Medicare Advantage members.

Aetna's Prior Authorization Submission Channels for Skyrizi

Aetna, a CVS Health-owned national insurer, utilizes distinct channels for prior authorization requests based on benefit category. For medical-benefit Skyrizi requests, Aetna primarily routes through the Availity provider portal. Additionally, Aetna supports X12 278 transactions via clearinghouses for applicable procedure categories. Pharmacy-benefit Skyrizi, if administered as an outpatient retail or mail-order prescription, would typically route through CVS Caremark, leveraging ePA partners like CoverMyMeds or Surescripts for retail pharmacy or CVS Caremark's direct portal for mail-order scenarios.

Aetna Medical Necessity Criteria and Policy for Risankizumab

Aetna's medical necessity criteria for specialty medications, including risankizumab, are published as Clinical Policy Bulletins (CPBs) in their public CPB library. These CPBs are versioned, dated, and provide specific guidelines regarding indications, step therapy requirements, and documentation needed for approval. Prior authorization teams must consult the current, applicable Aetna CPB for Skyrizi to understand the precise medical necessity logic, which may include requirements for prior therapies or specific diagnostic criteria.

Turnaround Times and Compliance Considerations

Prior authorization turnaround times for Aetna are influenced by several factors, including state-mandated minimums and NCQA Utilization Management accreditation standards. For Aetna's Medicare Advantage, Medicaid managed-care, and QHP-on-FFM lines of business, CMS-0057-F mandates 72-hour decisions for standard PA requests and 24-hour decisions for expedited PA requests, with phased compliance timelines. Commercial lines of business are not directly impacted by CMS-0057-F. Klivira helps track these diverse timelines to optimize submission and follow-up workflows.

Common Denial Reasons and Appeal Pathways for Skyrizi

Typical denial reasons for Skyrizi prior authorizations under Aetna often include insufficient documentation of medical necessity, failure to meet step therapy requirements, or off-label use without compendium support. Aetna returns denial reasons via X12 835/277 transactions or portal status updates, utilizing standard CARC and RARC vocabularies. The appeal pathway generally includes reconsideration, peer-to-peer review, and formal appeal processes, with specific timely-filing windows varying by line of business and state regulations.

Leveraging Electronic Prior Authorization (ePA) for Skyrizi

Aetna actively supports electronic prior authorization for pharmacy benefits through partnerships with CoverMyMeds and Surescripts. While medical-benefit ePA remains more fragmented, Klivira's platform integrates with various payer interfaces to facilitate electronic submissions where available, reducing manual effort. Klivira continuously monitors payer adoption of standards like Da Vinci PAS IG to ensure our clients benefit from evolving ePA capabilities, without making unverified claims about specific payer conformance.

Frequently asked questions

What is Skyrizi indicated for?

Skyrizi (risankizumab) is an IL-23 inhibitor indicated for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease.

How do I submit a medical benefit prior authorization for Skyrizi to Aetna?

For medical benefit Skyrizi, Aetna primarily directs prior authorization requests through the Availity provider portal. X12 278 transactions via clearinghouses are also supported for certain procedure categories.

Where can I find Aetna's medical necessity criteria for Skyrizi?

Aetna publishes its medical necessity criteria, including those for Skyrizi, in its public Clinical Policy Bulletins (CPBs) library. Always refer to the most current, applicable CPB for specific requirements.

Does Aetna require step therapy for Skyrizi?

Aetna's step therapy protocols are typically detailed within the applicable Clinical Policy Bulletins (CPBs). Prior authorization teams must consult the specific CPB for Skyrizi to determine any required preceding therapies.

What are common reasons for Aetna to deny Skyrizi prior authorizations?

Common denial reasons include insufficient documentation of medical necessity, failure to meet Aetna's step therapy requirements, or off-label use without adequate compendium support. Reviewing the specific denial reason codes (CARC/RARC) is crucial for effective appeals.

How does Klivira help with Aetna Skyrizi prior authorizations?

Klivira automates the prior authorization workflow by integrating with your EMR and Aetna's submission channels. This helps streamline documentation, track submission status, and manage follow-ups, reducing manual effort and accelerating approval times for Skyrizi.